Kangti Life has completed tens of millions of dollars in Series A+ funding.

On September 9th, Shenzhen Kangti Biomedical Technology Co., Ltd. announced the completion of Series A+ financing. As of now, the total funding amount has reached 70 million RMB, with investments from Jinyumao Wu, Lizhu Pharmaceutical, Xinghe Capital, and Nanling Fund. The funds will be used to further expand the company's technology platform and market layout in the field of nanobody discovery and modification services.